Exudative Age-related Macular Degeneration
Conditions
Interventions
lucentis
Sponsors
Department of Ophthalmology, Kagawa university faculty of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Willingness to provide written informed consent 2)BCVA: 0.1-1.0 3)AMD with Subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography 4)outpatient 5)In spite of performing medical treatment by eylea six months or more, it corresponds to a or b. a:There is no improvement of eyesight as compared with just before the medical treatment start by eylea.(0.3 or more logMAR conversion ) b:Even if it prescribes eylea for the patient 3 times or more, even when exudation is slight at OCT, it recurs to less than residual 3 month.
Exclusion criteria
Exclusion criteria: 1)Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2)Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3)Prior treatment with photodynamic therapy 4)Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5)Active intraocular inflammation 6)Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7)Patient who the doctor in charge judges are ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients in the maintenance or improvement in visual acuity 6 months after ranibizumab therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of (best-collected visual acuity) BCVA, central macular thickness, subretinal fluid, fundus autofluorescence | — |
Countries
Japan
Contacts
Public ContactMamoru Kobayashi
Kagawa university faculty of medicine Department of Ophthalmology
Outcome results
None listed